The impact of smoking cessation on multiple sclerosis disease progression

Author:

Rodgers Jeff1,Friede Tim2,Vonberg Frederick W3,Constantinescu Cris S4,Coles Alasdair5,Chataway Jeremy67,Duddy Martin8,Emsley Hedley910,Ford Helen11,Fisniku Leonora12,Galea Ian13,Harrower Timothy14,Hobart Jeremy15,Huseyin Huseyin16,Kipps Christopher M13,Marta Monica1718,McDonnell Gavin V19,McLean Brendan20,Pearson Owen R21,Rog David22,Schmierer Klaus1823,Sharrack Basil24,Straukiene Agne25,Wilson Heather C26,Ford David V1,Middleton Rod M1,Nicholas Richard1327,

Affiliation:

1. Population Data Science, Swansea University Medical School, Swansea, SA2 8PP, UK

2. Department of Medical Statistics, University Medical Center Göttingen, Göttingen, Germany

3. Department of Cellular and Molecular Neuroscience, Imperial College London, W12 0NN, UK

4. Division of Clinical Neuroscience, University of Nottingham, Nottingham, NG7 2UH, UK

5. Cambridge Neuroscience, University of Cambridge, Cambridge, CB2 3EL, UK

6. Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, United Kingdom WC1B 5EH

7. National Institute for Health Research, University College London Hospitals, Biomedical Research Centre, London, W1T 7HA, UK

8. Neurosciences, Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, NE7 7DN, UK

9. Lancaster Medical School, Faculty of Health & Medicine, Lancaster University

10. Lancaster, UK & Department of Neurology, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, PR1 2HE, UK

11. Centre for Neurosciences, Leeds Teaching Hospitals NHS Trust, Leeds General Infirmary, Great George Street, Leeds, LS1 3EX

12. Brighton and Sussex University NHS Trust, BN1 6AG, Brighton

13. Clinical Neurosciences, Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, SO17 1BJ, UK

14. Royal Devon and Exeter NHS Trust, Barrack Road, Exeter, EX25DW, UK

15. Plymouth University Peninsula Schools of Medicine and Dentistry, Consultant Neurologist, University Hospitals Plymouth, Room N13 ITTC Building, Plymouth Science Park, Davy Road, Plymouth, Devon, PL6 8BX, UK

16. Luton and Dunstable University Hospital, Bedfordshire Hospitals NHS Foundation Trust, Lewsey Road, Luton, LU4 0DZ, UK

17. Neurology - Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea SS0 0RY, UK

18. Blizard Institute, Royal London Hospital, Barts Health NHS Trust, London, E1 1BB, UK

19. MS Clinic, Belfast City Hospital, BHSCT, Belfast, BT9 7AB, UK

20. The Royal Cornwall Hospitals NHS Trust, Treliske, Truro TR1 3LJ, UK

21. Swansea Bay University Health Board, Swansea, SA6 6NL, UK

22. Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Stott Lane, Salford, M6 8HD, UK

23. Clinical Board Medicine (Neuroscience), Barts Health NHS Trust, The Royal London Hospital, London, UK

24. Department of Neurology and NIHR Neurosciences Biomedical Research Centre, Sheffield Teaching Hospitals NHS Foundation Trust and University of Sheffield, Sheffield, S10 2JF, UK

25. Torbay and South Devon NHS Foundation Trust, Torquay, TQ2 7AA, UK

26. National Hospital for Neurology and Neurosurgery, Queen Square, London, WC1H 3BG, UK

27. Department of Visual Neuroscience, UCL Institute of Ophthalmology, London, EC1V 9RL, UK

Abstract

Abstract The negative impact of smoking in MS is well established, however, there is much less evidence as to whether smoking cessation is beneficial to progression in MS. Adults with MS registered on the United Kingdom MS Register (2011-2020) formed this retrospective and prospective cohort study. Primary outcomes were changes in 3 patient reported outcomes (PROs): normalised MS Physical Impact Scale (MSIS-29-Phys), normalised MS Walking Scale (MSWS-12) and the Hospital Anxiety and Depression Scale (HADS-Anxiety and HADS-Depression). Time to event outcomes were clinically significant increases in the PROs. 7983 participants were included, 4130 (51.7%) of these had ever smoked; of whom 1315 (16.5%) were current smokers and 2815/4130 (68.2%) were former smokers. For all PROs, current smokers at the time of completing their first questionnaire had higher PRO scores indicating higher disability compared to those who had never smoked (∼10 points difference in MSIS-29-Phys and MSWS-12; 1.5-1.8 point for HADS-anxiety and HADS-depression). There was no improvement in PRO scores with increasing time since quitting in former smokers. 923 participants formed the prospective parallel group, which demonstrated that MSIS-29-phy 5.03, [3.71, 6.34], MSWS-12 5.28, [3.62, 6.94] and HADS-depression 0.71, [0.47, 0.96] worsened over a period of 4 years, whereas HADS-anxiety remained stable. Smoking status was significant at year 4; current smokers had higher MSIS-29-Phys and HADS-Anxiety scores (3.05 [0.22, 5.88], 1.14 [0.52,1.76]) while former smokers had a lower MSIS-29 score of -2.91[-5.03, -0.79]. 4642 participants comprised the time to event analysis. Still smoking was associated with a shorter time to worsening event in all PROs (MSIS-29-Phys: n = 4436, p = 0.0013; MSWS-12: n = 3902, p = 0.0061; HADS-anxiety: n = 4511, p = 0.0017; HADS-depression: n = 4511, p < 0.0001). Worsening in motor disability (MSIS-29-Phys and MSWS-12) was independent of baseline HADS-anxiety and HADS-depression scores. There was no statistically significant difference in the rate of worsening between never and former smokers. When smokers quit, there is a slowing in the rate of motor disability deterioration so that it matches the rate of motor decline in those who have never smoked. This suggests that smoking cessation is beneficial for people with MS.

Publisher

Oxford University Press (OUP)

Subject

Neurology (clinical)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3